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The balance between pro-inflammatory and immuno-
suppressive signals in the tumor microenvironment dic-
tates the responsiveness of the immune system. Local
radiotherapy (RT) has the potential to switch this bal-
ance in favor of anti-tumor immunity by promoting
cross-priming of anti-tumor T cells thus generating an
individualized in situ vaccine. We have previously
shown that the dose and fractionation employed modu-
late RT ability to synergize with immunotherapy.
Indeed, in two tumor models, generation of an in situ
vaccine synergistic with anti-CTLA-4 treatment was
achieved by irradiation of the tumor with 3 fractions of
8 Gy (8Gyx3) but not by a single 20 Gy dose (20Gyx1)
(Dewan et al., Clin Cancer Res 2009).
To understand the mechanisms underlying the different
outcome obtained with fractionated (3x8Gy) versus single
dose (20Gyx1) RT, TSA tumors growing in syngeneic
immunocompetent BALB/c mice were harvested at 4, 24
and 48 hrs post-RT for analysis of purified RNA by micro-
array for gene expression or infiltrating immune cells by
flow cytometry. Expression of key immune genes in TSA
cells irradiated in vitro was assessed by qPCR.
Over 100 immune response genes were differentially
expressed in irradiated tumors by 8Gyx3 but not 20Gyx1,
with a dominant type I interferon (IFN) response at 4
and 24 hours, which was confirmed by qRT-PCR. CD8a+
dendritic cells (DC), which are the subset of DC cross-
presenting tumor cell-derived antigens, showed a signifi-
cant upregulation of activation markers CD86, CD40 and
CD70 at 48 hours following 8Gyx3 but not 20 Gyx1.
Importantly, the in vitro setting (devoid of an immune
infiltrate) demonstrated expression of IFNb and down-
stream immune genes, including chemokines CXCL9,
CXCL10 and CXCL11 by TSA cells irradiated with
8Gyx3 but not 20Gyx1.
Data indicate that fractionated RT can mimic, at least in
part, a viral infection and activate canonical defense path-
ways in neoplastic epithelial cells with induction of type-I
IFN. In vivo this leads to activation of DC cross-presenting
tumor antigens, suggesting that the quality of fractionated-
RT generates the key “ingredients” of an in situ tumor vac-
cine. Further studies to identify the molecular mechanisms
of RT-induced tumor vaccination and their modulation by
different RT regimens are critical to the rational design of
clinical trials testing RT combinations with immunotherapy.
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